VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

McKesson Executive Compensation (FY26)

MCK · Executive and director compensation, fiscal 2022 to 2026
Chief executive, fiscal 2026
◇
Brian Tyler
Latest say-on-pay support
=
July 22, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on McKesson

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
15 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
McKesson brief$500Get the executive brief
Velarion Intel, one year, every company
307 figures on this page: 296 cited to the filing that reported them, 11 calculated from figures it prints. See the citations

More on McKesson

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2025 to fiscal 2026
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Brian Tyler: $20,161,714 → $24,213,044 (20.1% higher)
Say-on-pay support: 91.3% → 91.4% (0.1 points higher)
CEO pay ratio: 295:1 → 357:1 (21.0% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is McKesson's chief executive and what were they paid?
Total compensation for Brian Tyler, Chief Executive Officer, came to $24,213,044 in fiscal 2026. Compared with the $20,161,714 reported for fiscal 2025, Tyler's total was 20.1% higher.
What was McKesson's say-on-pay result?
For fiscal 2026, shareholders backed the say-on-pay proposal with 91.4% of votes cast including abstentions in favor at the meeting held July 22, 2026.
Which companies are in McKesson's peer group?
The disclosed peer group names Abbott Laboratories, Cardinal Health, Cencora, Costco and CVS Health, among others. The additional disclosed peer group names Accendra Health, Inc., Cencora, Cigna, CVS Health and Johnson & Johnson, among others. Companies named in the FY 2024 - FY 2026 Relative TSR Comparator Group (supplemental) include Accendra Health, Inc. (formerly Owens & Minor, Inc.), Sanofi and Viatris.
What is McKesson's chief executive pay ratio?
For fiscal 2026, the company reported a chief executive pay ratio of 357:1, against median employee compensation of $67,803.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Tyler
Chief Executive Officer
◇—◇—◇—◇◇
Britt Vitalone
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Lori Schechter
Former Executive Vice President, Chief Legal Officer and General Counsel
◇—◇—◇—◇◇
Tracy Faber
Executive Vice President and Chief Human Resources Officer
◇—◇—◇—◇◇
Nancy Avila
Former Executive Vice President, Chief Information Officer and Chief Technology Officer
◇—◇—◇—◇◇
Nancy Flores
Executive Vice President, Chief Information Officer and Chief Technology Officer
◇—◇—◇—◇◇
Thomas Rodgers
Executive Vice President and Chief Strategy and Business Development Officer
◇—◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Tyler
Chief Executive Officer
◇—◇—◇—◇◇
Britt Vitalone
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Lori Schechter
Former Executive Vice President, Chief Legal Officer and General Counsel
Departed during or after this year
◇—◇—◇—◇◇
Nancy Avila
Former Executive Vice President, Chief Information Officer and Chief Technology Officer
Departed during or after this year
◇—◇—◇—◇◇
LeAnn Smith
Executive Vice President and Chief Human Resources Officer
◇◇◇—◇—◇◇
Thomas Rodgers
Executive Vice President and Chief Strategy and Business Development Officer
◇—◇—◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Tyler
Chief Executive Officer
◇—◇—◇—◇◇
Michele Lau
Executive Vice President and Chief Legal Officer
◇◇◇—◇—◇◇
Britt Vitalone
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
LeAnn Smith
Executive Vice President and Chief Human Resources Officer
◇◇◇—◇—◇◇
Thomas Rodgers
Executive Vice President and Chief Strategy and Business Development Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Tyler
Chief Executive Officer
◇—◇—◇—◇◇
Britt Vitalone
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Michele Lau
Executive Vice President and Chief Legal Officer
◇—◇—◇—◇◇
LeAnn Smith
Executive Vice President and Chief Human Resources Officer
◇—◇—◇—◇◇
Thomas Rodgers
Executive Vice President and Chief Strategy and Business Development Officer
◇—◇—◇—◇◇
Fiscal 2026
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Tyler
Chief Executive Officer
◇—◇—◇—◇◇
Britt Vitalone
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Michele Lau
Executive Vice President and Chief Legal Officer
◇—◇—◇—◇◇
LeAnn Smith
Executive Vice President and Chief Human Resources Officer
◇—◇—◇—◇◇
Thomas Rodgers
Executive Vice President and Chief Strategy and Business Development Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2026
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian S. TylerRSU◇——◇——◇
Brian S. TylerPSU◇◇◇—◇—◇
Britt J. VitaloneRSU◇——◇——◇
Britt J. VitalonePSU◇◇◇—◇—◇
LeAnn B. SmithPSU◇◇◇—◇—◇
LeAnn B. SmithRSU◇——◇——◇
Michele LauRSU◇——◇——◇
Michele LauPSU◇◇◇—◇—◇
Thomas L. RodgersRSU◇——◇——◇
Thomas L. RodgersPSU◇◇◇—◇—◇
Fiscal 2022, 2025 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2026 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Brian TylerPSU◇◇——
RSU◇◇——
Britt VitalonePSU◇◇——
RSU◇◇——
Michele LauPSU◇◇——
RSU◇◇——
LeAnn SmithPSU◇◇——
RSU◇◇——
Thomas RodgersPSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Brian Tyler
Chief Executive Officer · Terms as described in the company’s compensation discussion
Severance cash amount◇
Benefits continuation on change in control◇
Benefits continuation◇
Britt Vitalone
Executive Vice President and Chief Financial Officer · Terms as described in the company’s compensation discussion
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
LeAnn Smith
Executive Vice President and Chief Human Resources Officer · Terms as described in the company’s compensation discussion
Severance cash amount◇
Benefits continuation on change in control◇
Michele Lau
Executive Vice President and Chief Legal Officer · Terms as described in the company’s compensation discussion
Severance cash amount◇
Benefits continuation on change in control◇
Thomas Rodgers
Executive Vice President and Chief Strategy and Business Development Officer · Terms as described in the company’s compensation discussion
Severance cash amount◇
Benefits continuation on change in control◇

Director compensation

What each non-employee director was paid.
Fiscal 2026
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Donald R. Knauss
Board chair
◇◇————◇
Dominic J. Caruso
Lead independent director
◇◇————◇
Bradley E. Lerman
◇◇————◇
Maria N. Martinez
◇◇————◇
Kevin M. Ozan
◇◇————◇
Julie L. Gerberding, M.D., M.P.H
◇◇————◇
Lynne M. Doughtie
◇◇————◇
Deborah Dunsire, M.D
◇◇————◇
James H. Hinton
◇◇————◇
W. Roy Dunbar
◇◇————◇
Kathleen Wilson-Thompson
◇◇————◇
Richard H. Carmona, M.D
◇◇————◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2026
  • Abbott Laboratories ABT
  • Cardinal Health CAH
  • Cencora COR
  • Costco COST
  • CVS Health CVS
  • Elevance Health ELV
  • FedEx FDX
  • HCA Healthcare HCA
  • Humana HUM
  • Johnson & Johnson JNJ
  • Kroger KR
  • Merck & Co. MRK
  • Pfizer PFE
  • Procter & Gamble PG
  • Sysco SYY
  • Target TGT
  • The Cigna Group CI
  • United Parcel Service UPS
  • UnitedHealth Group UNH
  • Walmart WMT
Additional disclosed peer group
  • Accendra Health, Inc. ACH
  • Cencora COR
  • Cigna CI
  • CVS Health CVS
  • Johnson & Johnson JNJ
  • Kroger KR
  • Pfizer PFE
  • Sanofi SNY
  • UnitedHealth Group UNH
  • Viatris VTRS
FY 2024 - FY 2026 Relative TSR Comparator Group (supplemental)
  • Accendra Health, Inc. (formerly Owens & Minor, Inc.) ACH
  • Sanofi SNY
  • Viatris VTRS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2026July 22, 2026=◇◇◇
2025July 30, 2025=◇◇◇
2024July 30, 2025=◇◇◇
2023July 21, 2023=◇◇◇
2022July 22, 2022=◇◇◇
2021July 23, 2021=◇◇◇
2020July 29, 2020=◇◇◇
2019July 31, 2019=◇◇◇
2018July 25, 2018=◇◇◇
2017July 26, 2017=◇◇◇
2016July 27, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Brian Tyler (Chief Executive Officer), FY2026 total compensation $24,213,044 (base salary $1,591,667) [exec_comp, SEC accession 0000927653-26-000169, filed 2026-06-12]

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Tell me when McKesson files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact McKesson disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where McKesson sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether McKesson's disclosed peer group is defensible, who names McKesson back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
307 figures on this page: 296 cited to the filing that reported them, 11 calculated from figures it prints.
296 cited to the filing
11 calculated from the filing

Documents cited

  1. 0000927653-26-000215
  2. 0000927653-26-000169
    CEO Pay Ratio · Compensation Discussion and Analysis · Director Compensation · Grants of Plan-Based Awards Table · and 2 more sections
  3. 0000927653-25-000096
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000927653-24-000065
    2024 Summary Compensation Table
  5. 0000927653-23-000045
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0000927653-22-000062
  7. 0001193125-22-171040
    2022 Summary Compensation Table
  8. 0000927653-21-000051
  9. 0000927653-20-000052
  10. 0001193125-19-212051
  11. 0001193125-18-228754
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-17-240424
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-16-663395
  14. 0001193125-23-164501
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “McKesson executive compensation, FY2022–FY2026.” https://intel.velarion.ai/comp/MCK (accessed 2026).
Short form: data: Velarion

The paid brief for McKesson

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$500 for the Executive Compensation Report. Both reports for $900.
15 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about McKesson and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.

Biopharma & Life Sciences rankings

Peers McKesson discloses

The companies named in MCK's own disclosed peer group.

Terms on this page

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}